Candel Therapeutics Appoints Carl H. June, M.D., Globally Recognized Immunotherapy Pioneer, To Its Research Advisory Board

Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies for cancer, has announced the appointment of Carl H. June, M.D., to its Research Advisory Board (RAB). Dr. June is internationally recognized as a leader in cancer immunotherapy and is best known as a pioneer in developing the first CAR-T cell therapy approved by the U.S. Food and Drug Administration (FDA). His expertise will support Candel’s efforts to advance its pipeline, including the viral immunotherapy candidate CAN-2409, which is being studied across multiple solid tumor indications, and CAN-3110 for recurrent high-grade glioma.

Dr. June, stated, “I'm pleased to join Candel’s Research Advisory Board at such a pivotal time for the Company. Candel's innovative approach to viral immunotherapy aligns with my passion for harnessing the power of the immune system to fight cancer. I look forward to contributing to the advancement of these promising therapies that have the potential to help patients across multiple cancer types.”

Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel, mentioned, “We are excited to expand our Research Advisory Board with the addition of Dr. June. His distinguished expertise in T cell engineering and immunology will provide an invaluable resource, as we advance CAN-2409 across multiple solid tumors, with an expected Biologics License Application (BLA) submission for prostate cancer in Q4 2026.”

Dr. June currently serves as the Richard W. Vague Professor in Immunotherapy within the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine, University of Pennsylvania. He is also the Director of the Center for Cellular Immunotherapies and the Director of the Parker Institute for Cancer Immunotherapy at the university. His research has been instrumental in understanding mechanisms of lymphocyte activation and their role in immune tolerance, as well as advancing adoptive immunotherapy strategies for both cancer and chronic infections.